Saturday 17 October 2026
Export REVB’s income statement to Excel — free account
Revelation Biosciences, Inc.
REVB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.9% and free cash flow fell 35.3%, each against the same quarter a year earlier.
0.49
0.27
−35.53%
Follow REVB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(205.92%) | (219.10%) | (271.02%) | (276.43%) | |
| (143.70%) | (163.31%) | (226.19%) | (214.63%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(127.98%) | (168.32%) | (166.32%) | (192.48%) | |
Free Cash Flow per Share |
(15.20) | (13.32) | (2.73) | (2.47) | |
Free Cash Flow |
(10.05) | (8.27) | (8.76) | (9.44) | |
Capital Expenditures |
— | — | (0.07) | (0.11) | |
| Other line items | |||||
Cash ROIC |
(42.39%) | (42.28%) | (32.33%) | (43.80%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.71 | 0.56 | 0.40 | 0.49 | |
Depreciation/Fixed assets |
1.19 | 1.50 | 0.19 | 0.16 | |
Capex/Depreciation |
0.00 | 0.00 | (2.65) | (3.95) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(15.20) | (13.32) | (2.71) | (2.44) | |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.03) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates